One of the main reasons I started MJ-UK was to make information available to all, and it’s something I’m really passionate about. In this new series, we’ll provide an update on the research that’s been published on Science Direct this week mentioning “Tirzepatide” (the drug name which is branded as Mounjaro in the UK) in non-technical terms.
Efficacy of glucagon-like peptide-1 receptor agonists for prevention of stroke among patients with and without diabetes: A meta-analysis with the SELECT and FLOW trails
Author: Gera et al. (2025)
Article Link: https://doi.org/10.1016/j.ijcha.2025.101638
Aim: To evaluate the impact of GLP-1 receptor agonists (i.e. Tirzepatide) on stroke risk, among patients with/without diabetes.
Population: Meta analysis of 11 studies, totalling 85,373 patients between active and placebo groups.
Results: GLP-1 RA’s reduced the risk of stroke by 15%, and non-fatal stroke by 13%.
Obesity Management in Primary Care: A Joint Clinical Perspective and Expert Review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP) – 2025
Author: Pennings et al. (2025)
Article Link: https://doi.org/10.1016/j.obpill.2025.100172
Aim: Examining obesity management from a primary care perspective; collaboration between the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP).
Conclusions: There are multiple barriers to effective care including; failure to recognise obesity as a disease, lack of accurate diagnosis, insufficient access to treatment, inadequate training, insufficient time, and adverse impact of bias, stigma, and discrimination.